Steroid-sparing strategies for managing immune-related adverse events
Although immune checkpoint inhibitors (ICI) have greatly improved outcomes in several cancer types, their use is also associated with immune-related adverse events (irAEs) that can impact any organ system and lead to significant morbidity and even mortality. Current approaches to treatment of irAEs...
Збережено в:
| Автори: | , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
BMJ Publishing Group
2026-01-01
|
| Серія: | Journal for ImmunoTherapy of Cancer |
| Онлайн доступ: | https://jitc.bmj.com/content/14/1/e013776.full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|